Author/Authors :
Einollahi, B. baqiyatallah university of medical sciences - Nephrology and Urology Research Center, ايران , Alavian, S. M. baqiyatallah university of medical sciences - Baqiyatallah Research Center for Gastroenterology and Liver Disease, ايران , Lessan-Pezeshki, M. tehran university of medical sciences tums - Department of Nephrology, تهران, ايران , Simforoosh, N. shahid beheshti university of medical sciences - Renal Transplantation Center, تهران, ايران , Nourbala, M. H. baqiyatallah university of medical sciences - Nephrology and Urology Research Center, ايران , Rostami, Z. baqiyatallah university of medical sciences - Nephrology and Urology Research Center, ايران , Pourfarziani, V. baqiyatallah university of medical sciences - Nephrology and Urology Research Center, ايران , Nemati, E. baqiyatallah university of medical sciences - Nephrology and Urology Research Center, ايران , Sharafi, M. baqiyatallah university of medical sciences - Nephrology and Urology Research Center, ايران , Nafar, M. shahid beheshti university of medical sciences - Renal Transplantation Center, تهران, ايران , Pour-Reza Gholi, F. shahid beheshti university of medical sciences - Renal Transplantation Center, تهران, ايران , Firoozan, A. shahid beheshti university of medical sciences - Renal Transplantation Center, تهران, ايران
Abstract :
Background: With the success of kidney transplantation, liver disease has emerged as an important cause of morbidity and mortality in kidney recipients.Objective: To determine the impact of hepatitis B virus (HBV) infection on patients and graft survival in both short- and long-terms.Methods: 99 renal transplant patients infected with HBV on follow-up in two major transplant centers were included in a retrospective study. These patients were grafted between 1986 and 2005 and divided into two groups: (1) those only positive for hepatitis B surface antigen (HBsAg) and (2) those who were also positive for hepatitis C virus antibodies (HCV Ab).Results: There were 88 patients with HBsAg+ and 11 with both HBsAg+ and HCV Ab+. The mean±SD age of patients was 38.8±13.2 years, and the median follow-up after transplantation was 19 months. Although not significant, the allograft survival rate in the first group (HBV+) was better compared to that in the second group (HBV+ and HCV+); 1, 5 and 10 years graft survival rates were 91, 77 and 62 in the first group and 70, 56 and 28 in the second group, respectively (P=0.07). The overall mortality was 5% (4 of 88) in the first and 27% (3 of 11) in the second group (P=0.02).Conclusion: Renal allograft recipients with HBV and HCV infections has a poor survival rate compared to patients with only HBV infection. However, there is no significant difference in terms of renal graft survival between the two groups
